Surrozen, Inc./DE Payments to Acquire Marketable Securities
Surrozen, Inc./DE (SRZN) reported Payments to Acquire Marketable Securities of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2025-03-31
- Surrozen, Inc./DE payments to acquire marketable securities for the quarter ending 2024-12-31 was $0.00.
- Surrozen, Inc./DE payments to acquire marketable securities for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Surrozen, Inc./DE payments to acquire marketable securities for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- Surrozen, Inc./DE payments to acquire marketable securities for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Surrozen, Inc./DE payments to acquire marketable securities for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Surrozen, Inc./DE payments to acquire marketable securities for fiscal 2023 was $28.04M, a 5.26% decline from fiscal 2022.
- Surrozen, Inc./DE payments to acquire marketable securities for fiscal 2022 was $29.60M, a 67.73% decline from fiscal 2021.
- Surrozen, Inc./DE payments to acquire marketable securities for fiscal 2021 was $91.74M, a 546.00% increase from fiscal 2020.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $0.00 derived: sum of 3 quarters · filed 2025-03-31 | $0.00 10-K · filed 2025-03-31 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | $0.00 derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $0.00 10-Q · filed 2024-08-12 | $0.00 derived: sum of 3 quarters · filed 2025-03-31 | $9.35M derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-08 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $9.35M derived: sum of 3 quarters · filed 2025-03-31 | $20.19M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $9.35M derived: sum of 2 quarters · filed 2025-03-31 | $20.19M derived: sum of 3 quarters · filed 2025-03-31 | $28.04M 10-K · filed 2025-03-31 |
| 2023-09-30 | $9.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $20.19M derived: sum of 2 quarters · filed 2024-11-06 | $28.04M 10-Q · filed 2024-11-06 | $36.75M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $10.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $18.69M 10-Q · filed 2024-08-12 | $27.40M derived: sum of 3 quarters · filed 2024-08-12 | $48.29M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $7.86M 10-Q · filed 2024-05-08 | $16.56M derived: sum of 2 quarters · filed 2024-05-08 | $37.46M derived: sum of 3 quarters · filed 2024-05-08 | $37.46M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $8.71M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-10 | $29.60M derived: sum of 2 quarters · filed 2024-04-10 | $29.60M derived: sum of 3 quarters · filed 2024-04-10 | $29.60M 10-K · filed 2024-04-10 |
| 2022-09-30 | $20.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $20.89M derived: sum of 2 quarters · filed 2023-11-08 | $20.89M 10-Q · filed 2023-11-08 | $38.29M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $0.00 10-Q · filed 2023-08-09 | $17.40M derived: sum of 3 quarters · filed 2023-08-09 | $90.64M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-10 | $17.40M derived: sum of 2 quarters · filed 2023-05-10 | $90.64M derived: sum of 3 quarters · filed 2023-05-10 | $90.64M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $17.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $90.64M derived: sum of 2 quarters · filed 2023-03-31 | $90.64M derived: sum of 3 quarters · filed 2023-03-31 | $91.74M 10-K · filed 2023-03-31 |
| 2021-09-30 | $73.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $73.24M derived: sum of 2 quarters · filed 2022-11-14 | $74.34M 10-Q · filed 2022-11-14 | $88.54M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $1.10M 10-Q · filed 2022-08-11 | $15.30M derived: sum of 3 quarters · filed 2022-08-11 | |
| 2021-03-31 | $1.10M 10-Q · filed 2022-05-11 | $15.30M derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2020-12-31 | $14.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $14.20M 10-K · filed 2022-03-28 | ||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |